AU2005256944A1 - Use of reboxetine for the treatment of pain - Google Patents

Use of reboxetine for the treatment of pain Download PDF

Info

Publication number
AU2005256944A1
AU2005256944A1 AU2005256944A AU2005256944A AU2005256944A1 AU 2005256944 A1 AU2005256944 A1 AU 2005256944A1 AU 2005256944 A AU2005256944 A AU 2005256944A AU 2005256944 A AU2005256944 A AU 2005256944A AU 2005256944 A1 AU2005256944 A1 AU 2005256944A1
Authority
AU
Australia
Prior art keywords
pain
reboxetine
pharmaceutically acceptable
treatment
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005256944A
Other languages
English (en)
Inventor
Bernadette Hughes
Ian Mckenzie
Malcolm John Stoker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412878A external-priority patent/GB0412878D0/en
Priority claimed from GB0425061A external-priority patent/GB0425061D0/en
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2005256944A1 publication Critical patent/AU2005256944A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005256944A 2004-06-09 2005-05-27 Use of reboxetine for the treatment of pain Abandoned AU2005256944A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0412878.1 2004-06-09
GB0412878A GB0412878D0 (en) 2004-06-09 2004-06-09 Use
US58865204P 2004-07-16 2004-07-16
US60/588,652 2004-07-16
GB0425061.9 2004-11-12
GB0425061A GB0425061D0 (en) 2004-11-12 2004-11-12 Use
US63442704P 2004-12-07 2004-12-07
US60/634,427 2004-12-07
PCT/IB2005/001904 WO2006000903A2 (en) 2004-06-09 2005-05-27 Use of reboxetine for the treatment of pain

Publications (1)

Publication Number Publication Date
AU2005256944A1 true AU2005256944A1 (en) 2006-01-05

Family

ID=34979099

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005256944A Abandoned AU2005256944A1 (en) 2004-06-09 2005-05-27 Use of reboxetine for the treatment of pain

Country Status (12)

Country Link
US (1) US20080261984A1 (enExample)
EP (1) EP1763354A2 (enExample)
JP (1) JP2008501778A (enExample)
KR (1) KR20070029740A (enExample)
AU (1) AU2005256944A1 (enExample)
BR (1) BRPI0511941A (enExample)
CA (1) CA2567365A1 (enExample)
IL (1) IL178827A0 (enExample)
MX (1) MXPA06014389A (enExample)
NO (1) NO20064642L (enExample)
RU (1) RU2006143659A (enExample)
WO (1) WO2006000903A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20130310385A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
EP3782627A4 (en) * 2018-04-17 2021-07-07 Shanghai Tonglian Pharmaceutical Co., Ltd. MEDICINAL PRODUCT USED TO PREVENT AND / OR TREAT PAIN AND / OR FEVER, A COMBINATION PRODUCT, AND USE OF THEM
WO2019222850A1 (en) * 2018-05-23 2019-11-28 Wex Pharmaceuticals Inc. Synergistic tetrodotoxin formulations and methods of treatment for neuropathic pain
WO2019245975A1 (en) * 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
BR112021007019A2 (pt) * 2018-10-15 2021-07-13 Axsome Therapeutics, Inc. uso de reboxetina para tratar narcolepsia
US12616702B2 (en) * 2019-12-03 2026-05-05 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
CR20220247A (es) * 2019-12-03 2022-08-18 Axsome Therapeutics Inc Uso de reboxetina para tratar los trastornos del sistema nervioso
US20260174699A1 (en) * 2024-12-23 2026-06-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising uniform blends of reboxetine
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US422449A (en) * 1890-03-04 Gage for gas-cocks
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE305788T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
SI1196172T1 (sl) * 1999-07-01 2006-06-30 Pharmacia & Upjohn Co Llc (S,S)-reboksetin za zdravljenje kronicne bolecine
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
MXPA06002778A (es) * 2003-09-09 2006-06-14 Pfizer Prod Inc Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
ATE449633T1 (de) * 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern

Also Published As

Publication number Publication date
US20080261984A1 (en) 2008-10-23
MXPA06014389A (es) 2007-02-19
WO2006000903A2 (en) 2006-01-05
CA2567365A1 (en) 2006-01-05
WO2006000903A3 (en) 2006-06-08
IL178827A0 (en) 2007-03-08
NO20064642L (no) 2006-11-13
EP1763354A2 (en) 2007-03-21
RU2006143659A (ru) 2008-06-20
JP2008501778A (ja) 2008-01-24
KR20070029740A (ko) 2007-03-14
BRPI0511941A (pt) 2008-01-22

Similar Documents

Publication Publication Date Title
CN104968368B (zh) 固溶体组合物及其在剧痛中的用途
MXPA06003157A (es) Combinaciones de ligandos alfa-2-delta e inhibidores de la acetilcolina esterasa.
US20080261984A1 (en) Use of S,S-Reboxetine in the Treatment of Pain
US20120277319A1 (en) Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety
CN102573823B (zh) 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
US10695432B2 (en) Solid solution compositions and use in severe pain
CN103179962A (zh) 丙二腈酰胺类似物在神经病理性疼痛中的用途
US11918654B2 (en) Solid solution compositions and use in severe pain
US20170043016A1 (en) Solid Solution Compositions and Use in Severe Pain
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
JP6116673B2 (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびガバペンチノイドを含む医薬組成物
US10813891B2 (en) Method of inhibiting chronification of pain
JP6116679B2 (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよび抗けいれん剤を含む医薬組成物
CA2537402C (en) Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
ES2987503T3 (es) Compuestos que tienen afinidad por el receptor de melatonina como agente profiláctico o terapéutico para el delirio confusional
JP6116676B2 (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびパラセタモールまたはプロパセタモールを含む医薬組成物
JP6116678B2 (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびＮＳＡＲを含む医薬組成物
JP6116677B2 (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびオキシカムを含む医薬組成物
CN101208095A (zh) 瑞波西汀在治疗疼痛中的应用
HK1113092A (en) Use of reboxetine for the treatment of pain
JP2017052778A (ja) 三叉神経因性痛に伴う疼痛の治療用タペンタドール
CA2338327A1 (en) Use of moclobemide for treating pain and other diseases
MD3996699T2 (ro) Combinație de ibuprofen și tramadol pentru calmarea durerii
WO2025254184A1 (ja) 肥満状態に起因する疾患の予防及び治療用医薬
TW200523257A (en) Use of organic compounds

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period